Table 3 Baseline characteristics of subjects in the double-blind study
Variable | Chloroquine group | Placebo group | P value |
|---|---|---|---|
Gender (F/M) | 44/12 | 33/18 | 0.1108 |
Age | 55 ± 12 | 55 ± 9 | 0.9999 |
Race (AA/NHW/H/NA) | 9/45/1/1 | 6/45/0/0 | 0.4990 |
Smoking status | |||
 Current | 8 | 10 | 0.4341 |
 Past | 21 | 23 | 0.2962 |
Statin treatment | 15 | 15 | 0.8310 |
Hypertension treatment | 20 | 19 | 0.9999 |
Fish oil treatment | 5 | 10 | 0.1632 |
Waist circumference | 110.4 ± 10.5 | 108.9 ± 11.8 | 0.6538 |
BMI | 36.2 ± 5.0 | 34.2 ± 5.0 | 0.0433* |
SBP | |||
 Screen | 137.1 ± 14.3 | 140.2 ± 13.2 | 0.2385 |
 Randomization | 129.2 ± 11.4 | 134.0 ± 10.1 | 0.0237* |
DBP | |||
 Screen | 82.8 ± 9.5 | 83.0 ± 9.7 | 0.9483 |
 Randomization | 78.3 ± 7.4 | 79.7 ± 7.2 | 0.3244 |
Glucose | 5.48 ± 0.53 | 5.52 ± 0.64 | 0.6960 |
Triglycerides | 1.84 ± 1.04 | 1.82 ± 0.93 | 0.9155 |
HDL-C | 1.14 ± 0.26 | 1.14 ± 0.27 | 0.9603 |
Cholesterol | 5.00 ± 0.85 | 5.18 ± 1.15 | 0.3834 |
LDL-C | 3.04 ± 0.68 | 3.28 ± 0.82 | 0.1073 |